You are here

Takeda

Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

BioSpace

Flag link:

Charles River pens Takeda early-stage drugs deal

Charles River pens Takeda early-stage drugs deal

Fierce Biotech

Charles River Laboratories

Flag link:

Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration

Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration

Xconomy

artificial intelligence

Flag link:

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Fierce Pharma

Flag link:

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

BioSpace

Turnstone Biologics

Flag link:

Takeda and Cerevance Team Up to Take on GI Diseases

Takeda and Cerevance Team Up to Take on GI Diseases

BioSpace

gastrointestinal disease

Flag link:

As NASH shifts again, the focus remains on Genfit’s big readout

As NASH shifts again, the focus remains on Genfit’s big readout

EP Vantage

Boehringer Ingelheim

Gilead Sciences

Intercept Pharma

Flag link:

ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

Fierce Pharma

Flag link:

Takeda's dengue vaccine efficacy slips between 12- and 18-month analyses

Takeda's dengue vaccine efficacy slips between 12- and 18-month analyses

Fierce Pharma

Flag link:

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Pharmaforum

clinical trials

ALK-positive non-small cell lung cancer

Flag link:

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Fierce Pharma

ALK-positive non-small cell lung cancer

Flag link:

Takeda sees cell, gene therapy in its future. Is it too late?

Takeda sees cell, gene therapy in its future. Is it too late?

Biopharma Dive

Flag link:

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

Endpoints

Finch Therapeutics

Crohn's Disease

Flag link:

Orphan Drug Recall Leaves Patients in the Lurch

Orphan Drug Recall Leaves Patients in the Lurch

RAPS.org

hypoparathyroidism

product recalls

Flag link:

Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma

Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma

Fierce Pharma

Multiple Myeloma

clinical trials

Flag link:

Early data on Takeda's dengue vaccine is promising, but wait for the full dataset

Early data on Takeda's dengue vaccine is promising, but wait for the full dataset

Endpoints

clinical trials

Flag link:

Takeda's dengue shot 80% effective in massive phase 3 test

Takeda's dengue shot 80% effective in massive phase 3 test

Fierce Pharma

clinical trials

Flag link:

Takeda nets $660m from product selloff to Germany’s Stada

Takeda nets $660m from product selloff to Germany’s Stada

Pharmaforum

Flag link:

Takeda acquires TAK-101 license from COUR in $420m deal

Takeda acquires TAK-101 license from COUR in $420m deal

Pharmaceutical Business Review

COUR Pharmaceutical Development

Flag link:

Takeda pares down products and jobs, revives Genzyme building plans

Takeda pares down products and jobs, revives Genzyme building plans

Bizjournals

Flag link:

Pages